Ripple CEO predicts crypto current market will double in dimension to $5 trillion by the end of 2024

Ripple CEO predicts crypto current market will double in dimension to  trillion by the end of 2024


Critical Points
  • Ripple CEO Brad Garlinghouse reported he expects the total price of the crypto market to double this year, citing the arrival of the first U.S. location bitcoin exchange-traded fund and upcoming so-known as bitcoin “halving.”
  • “The total sector cap of the crypto business … is quickly predicted to to double by the stop of this calendar year … [as it’s] impacted by all of these macro aspects,” Garlinghouse mentioned.
  • 1 of the other aspects Garlinghouse sees pushing the crypto market place to new highs is the probability of favourable regulatory momentum in the United States.



Resource

These underperforming groups may deliver AI-electric appeal. Here’s why.
Finance

These underperforming groups may deliver AI-electric appeal. Here’s why.

ETF Edge These underperforming groups may deliver AI-electric appeal. Here’s why. Published Sat, Nov 15 202511:00 AM EST Blair Bao WATCH LIVE Source

Read More
Warren Buffett’s Berkshire Hathaway reveals new position in Alphabet
Finance

Warren Buffett’s Berkshire Hathaway reveals new position in Alphabet

Warren Buffett speaks during the Berkshire Hathaway Annual Shareholders Meeting in Omaha, Nebraska on May 3, 2025. CNBC Warren Buffett’s Berkshire Hathaway revealed a new position in Alphabet, making the Google parent the conglomerate’s 10th largest equity holding at the end of September, according to a regulatory filing. Berkshire disclosed a $4.3 billion stake in […]

Read More
Stocks making the biggest moves midday: Whirlpool, Topgolf Callaway, Nvidia, Stubhub & more
Finance

Stocks making the biggest moves midday: Whirlpool, Topgolf Callaway, Nvidia, Stubhub & more

Check out the companies making the biggest moves midday: Scholar Rock — The Cambridge, Massachusetts-based biotech jumped 23% after saying it ” completed constructive and collaborative in-person Type A meeting ” with the FDA on Wednesday for a biologics license application for apitegromab, a spinal muscular atrophy treatment. Officials from Novo Nordisk’s Catalent Indiana joined […]

Read More